PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontimmuLink to Publisher's site
 
Front Immunol. 2017; 8: 285.
Published online 2017 March 20. doi:  10.3389/fimmu.2017.00285
PMCID: PMC5357778

Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production

Abstract

Background

Rheumatoid arthritis (RA) is an inflammatory debilitating disease that affects the joints in the early and productive phases of an individual’s life. Several cytokines have been linked to the disease pathogenesis and are known to contribute to the inflammatory state characteristic of RA. The participation of type I interferon (IFN) in the pathogenesis of the disease has been already described as well as the identity of the genes that are regulated by this molecule, which are collectively known as the type I IFN signature. These genes have several functions associated with apoptosis, transcriptional regulation, protein degradation, Th2 cell induction, B cell proliferation, etc. This article evaluated the expression of several genes of the IFN signature in different stages of disease and their correlation with the levels of anticitrullinated protein antibodies (ACPA) anticarbamylated protein (Anti-CarP) antibodies.

Methods

Samples from individuals with early and established RA, high-risk individuals (ACPA+ and ACPA−), and healthy controls were recruited at “Unidad de Artritis y Rheumatismo” (Rheumatism and Arthritis Unit) in Guadalajara Jalisco Mexico. Determinations of ACPA were made with Eurodiagnostica ACPA plus kit. Anti-CarP determinations were made according to previously described protocols. RNA was isolated, and purity and integrity were determined according to RNA integrity number >6. Gene expression analysis was made by RT-qPCR using specific primers for mRNAs of the type I IFN signature. Relative gene expression was calculated according to Livak and Schmitgen.

Results

Significant differences in gene expression were identified when comparing the different groups for MXA and MXB (P < 0.05), also when comparing established RA and ACPA− in both IFIT 1 and G15. An increased expression of ISG15 was identified (P < 0.05), and a clear tendency toward increase was identified for HERC5. EPSTRI1, IFI6, and IFI35 were found to be elevated in the chronic/established RA and early RA (P < 0.05). Significant correlations were identified for the IFN signature genes with the levels of ACPA and anti-CarP (P < 0.05).

Conclusion

Our data confirm previous observations in the role of IFN signature and the pathogenesis of RA. Also, we provide evidence of an association between several genes of the IFN signature (that regulate Th2 cells and B cell proliferation) with the levels of anti-CarP antibodies and ACPA.

Keywords: rheumatoid arthritis, biomarkers, interferon-1 signature, anticarbamylated protein, anticitrullinated protein antibodies

Introduction

Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease that affects mainly the diarthrodial joints and is the cause of progressive and incapacitating joint destruction. Systemic manifestations are also present in individuals suffering from the disease, which can be classified as extraarticular manifestations. It is characterized by the presence of inflammatory immune cells in the joints. RA evolves toward a state of synovial hyperplasia, which is the cause of loss of bone structure and functional impairment. Several studies in North America and northern Europe show a prevalence of 0.5–1.1%, whereas in south of Europe, the reported prevalence is of 0.3–0.7%. Few studies have been performed in developing countries using the American College of Rheumatology 1987 criteria (1), showing a prevalence of 0.1–0.5%. However, it is difficult to establish whether this low prevalence is true or represents a referral bias due to the characteristics of healthcare in developing countries (2).

Rheumatoid arthritis affects multiple dimensions of the quality of life of not only patients but also caregivers, such as the physical, emotional, affective and the economy of the family and the health care institutions, all of this accompanied of productivity loss (3). It has been estimated in Mexico that the financial burden of RA on the patient’s families is of 610 ± 302.2 USD/year, whereas the direct costs of RA for the health institutions is of 1,724.00 USD/year/patient generating a great burden in the financial viability of public health care institutions (4). In addition, there is also an increased frequency in the use of biologics such as etanercept, infliximab, adalimumab, and rituximab, increasing significantly the cost of each patient’s treatment.

Several risk factors for RA have been identified, such as allelic variants of HLA-DR 01, 04, and others of the shared epitope (5). Also, several genes like the PAD4 or CTLA4 have been identified as independent risk factors for the disease (6). Modifiable risk factors such as smoking habits have been associated with severity of RA and with the presence of autoantibodies (7). Other diseases such as periodontal disease and gingivitis associated with several bacterial species such as PAD-like-producing Porphyromonas gingivalis have been speculated to increase the availability of citrullinated antigens and therefore the probability of autoantibody generations against such antigens (8). Differences in age for the onset of RA and its symptoms have been proposed to be not only due to the exposure to UV radiation (9) but also due to pesticides, in both the domestic and work environments altering some mechanisms of the oxidative stress response and contributing to tissue damage and RA initiation (10).

The etiology of RA is complex; however, several components of the immune response have been linked to RA physiopathology (11). It has been described the important role of macrophages, dendritic cells, and neutrophils in joint inflammation and synovial destruction in the initial phases of the disease, as the result of type I and II interferons (IFNs) activating myeloid cells and helping to sustain the inflammatory process through the production of cytokines such as IL-6 and TNF-α (12). Synovial fibroblasts also contribute to this process due to increased responsiveness to inflammatory stimuli and reduced apoptosis, perpetuating it (13). Also, this inflammatory milieu and the increased availability of citrullinated and carbamylated antigens lead to the production of autoantibodies (14). Neutrophils contribute to the aforementioned process through the induction of RANK/RANKL activation of osteoclasts, and this has been associated with an increased severity of RA (15). Khandpur et al. have documented that neutrophils of RA patients are more prone to neutrophil extracellular trap formation, and given that these neutrophil-derived structures are rich in citrullinated antigens, they propose that these mechanisms are the ones responsible for autoantibody generation (16).

T cells, both CD4+ and CD8+ are also important actors in the inflammatory response in the synovia, the latter recently linked to increased citrullination through pore-forming mechanisms (17). In a similar fashion, the function of CD4+ Th2 lymphocytes has been suggested to be linked to autoantibody generation and to response polarization through interaction of CD40 and CD40L (18), as well as that mediated by OX-40 and OX40L (19) appear to have a preponderant role in autoantibody production, and these antibodies have an important role in the pathogenesis of disease (20). In the ACR/EULAR2010 criteria, anticitrullinated protein antibodies (ACPA) are considered an important tool to define the disease (21). The increase in ACPA levels is known to precede the onset of symptoms in first-degree relatives of RA patients, and there is also an increased risk of developing RA for the ACPA+ individuals (22). Recently, the presence of anticarbamylated protein (anti-CarP) has also been associated with RA severity and RA in undifferentiated arthralgia (23). This suggests that both ACPA and anti-CarP antibodies might have an important participation in the initiation of symptoms, in the early stages of the disease, and also as markers of tolerance loss (23, 24). Moreover, it has been suggested that in the early stages of RA, type I IFNs might have an important role in the phenomenon of loss of tolerance, and in the chronic or established phase of RA, these molecules contribute to the perpetuation of the inflammatory response (25). Several of the type I IFN genes have been linked to antiviral and immunomodulatory activities (26). Type I IFNs induce dendritic cell maturation and the expression of both co-stimulatory and MHC I/II molecules as well as an increase in cytokine expression (27). Type I IFNs are produced mainly by plasmacytoid dendritic cells in response to a plethora of stimuli such as viral DNA and RNA or due to immune complexes of DNA/RNA antibody (28). IFN-α promotes dendritic cell differentiation and Th0 cell polarization to Th1 and also the cytotoxic response of CD8+ lymphocytes and NKT cells. It has also been described to induce B cell differentiation and antibody production and class switch to IgG (26). In RA, it has been described that immune complexes are produced due to an increased susceptibility to netosis of neutrophils (16), and also autoantibodies could be mediating this process acting as endogenous activators of IFN-α production (29). Although such mechanisms were first described for systemic lupus erythematosus (SLE) (30, 31), recent evidence suggest their participation in other autoimmune diseases such as RA (32). The genes activated through the described mechanism are known as IFN signature and comprise genes such as MXA and MXB associated with antiviral response (33, 34); IFIT1 and IFIT2 linked to posttranscriptional regulation in viral infections (35); ISG15 and 55 as part of the proteasomal degradation machinery (36); LY6E and RSAD2 are involved in metabolism and proliferation regulation of B cells (37); also, EPSTRI1, IFI44L, and IFI35 (38) are thought to participate in IFN signature response modulation. IFI6 has been described to participate in apoptosis inhibition mediated by TRAIL (39).

In other autoimmune diseases such as SLE, the immune complexes have been described to be internalized by pDC through the Fc-γRIIA into endosomes and interact with TLR7 and TLR9. After this activation, MyD88 induces activation and phosphorylation and translocation to the nucleus of the IFN-regulating factor 7 nuclear factor, inducing the transcription of the type I IFN genes (40).

Van der Pouw Kraan and colleagues identified several changes in gene expression in the IFN signature in established RA compared to control individuals (25), but the early stages of RA [early RA (eRA)] or the preclinical autoimmune phase of the disease was not the focus of that publication, and there are no available data regarding the role of the induced genes in these preclinical or early stages of the disease. Because of the direct association of several genes of the IFN signature with the physiopathology of RA, the natural history of the disease, and the expansion, regulation, and function of B cells, it is important to understand the relationship of the IFN signature activation and gene expression with the levels of ACPA and anti-CarP. The aims of this article were to analyze whether type I IFN-regulated genes were underexpressed or overexpressed in several groups of individuals at high risk of developing RA and in people with early or established disease and also to evaluate their relationship with autoantibodies in serum.

Materials and Methods

Patients

The study participants were recruited between 2012 and 2014 at a Rheumatology Clinic in Guadalajara, Jalisco, Mexico, and at the “Emilio Varela Lujan” General Hospital of Zacatecas, Mexican Institute of Social Security (IMSS). Patients with eRA <2 years of symptoms without treatment (41) and chronic/established RA (cRA) with an evolution of >2 years and treated with disease-modifying antirheumatic drugs (DMARD) were recruited. All study participants were evaluated by board-certified rheumatologists, and diagnosis was confirmed or ruled out according to the 2010 revised European League Against Rheumatism/ACR criteria (42). Informed consent was obtained from all participants. This consent was approved by the local Ethics Committee (IMSS; R-2013-785-009). First-degree relatives of patients with confirmed RA were invited to participate in the study and were categorized into two groups: those negative (ACPA−) and positive (ACPA+) for ACPA. Unrelated healthy control (HC) subjects without self-reported history of autoimmune diseases, malignancy, or infectious diseases (HIV and HCV) were also enrolled. Blood samples were drawn for all subjects, and RNA later (Invitrogen) was used for RNA stabilization. Blood samples treated with RNA later and serum samples were stored at −20°C until use.

RNA Extraction, Quality Control, and cDNA Synthesis

RNA isolation was performed according to a QIAamp protocol (Qiagen, Germany) adapted in our laboratory. Briefly whole blood samples that had been previously stabilized were unfrozen at room temperature and mixed vigorously in a 15-ml conical tube, and chloroform was added to the sample and subjected to centrifugation. The aqueous phase was transferred to another tube, and precipitation of RNA was made by means of ethanol. The mix was passed through a QIA-shredder spin column, and samples were processed as recommended by the supplier by another step of column purification and RNAse-free DNA digestion in column. Elution of the purified RNA was made in RNAse-free, diethyl pyrocarbonate (Sigma, St. Louis)-treated water. RNA integrity was assessed with the Bionalyzer 2100 (Agilent technologies, USA), and samples with RNA integrity number >6 were used. The conversion of RNA to cDNA was made by means of the Superscript II reverse transcriptase kit (Invitrogen, USA), briefly, 2.5 μg of total RNA was retrotranscribed according to the manufacturers protocol in a Biometra Gradient model T thermal cycler (Thermo Corp., Germany). cDNA was treated with DNAse-free RNAse H, and aliquots of cDNA at a concentration of 25 ng/μl were prepared for the qPCR assays.

Gene Expression Analysis

Oligonucleotides and probes used in the qPCR assays were designed in the ROCHE Universal Probe Library. All assays were carried out in a Lightcycler 480 (ROCHE, USA) and with the light cycler Taqman Master kit (Roche, USA) with a cycling program as follows: preincubation 95°C/10 min, 45 cycles (denaturation 95°C/10s, Hyb 65°C/30s, and extension 70°C/1s), and cooling to 40°C. From the amplification curves, Ct was obtained for each sample, for both the problem genes (Table (Table1;1; IFN signature genes) and the constitutive gene hypoxanthine phosphoribosyltransferase. Gene expression analysis was calculated with the 2−ΔΔCt using the HC group as a reference.

Table 1
Primer sequences for qPCR.

ACPA and Anti-CarP Antibody Determinations

Serum samples collected from the participants were used for autoantibody (ACPA and Anti-CarP antibodies) measurements. Determination of anti-CCP2 antibodies was performed using enzyme-linked immunosorbent assays according to the manufacturer’s instructions (Euro-Diagnostica, Malmö, Sweden). The cutoff value for positivity was set at 25 arbitrary units/ml according to the suggestion of the manufacturer. Determination of anti-CarP was made as described before (43). The plates were incubated with carbamylated or uncarbamylated fetal calf serum (half plate each), washed with PBS/0.05% Tween (Sigma, USA), and subsequently blocked for 6 h at 4°C with 100 μl of PBS/1% BSA (Sigma, USA). After washing, the wells were incubated with 50 μl serum 1/50 diluted in PBS/1% BSA/0.05% Tween. Antibodies were detected using horseradish peroxidase (HRP)-conjugated rabbit anti-human Ig antibody (ABCAM, UK), and HRP-conjugated HRP enzyme activity was visualized using ABTS (PeproTech, UK). As a standard, serial dilutions of a pooled serum sample from a patient with RA were used.

Statistical Analysis

Normality of data was assessed by a D’Agostino-Pearson normality test. According to data distribution, the multiple comparisons tests were performed: Kruskal–Wallis test with Dunn post hoc test was used for non-normally distributed data and the parametric one-way ANOVA with Tukey post hoc test, for the normally distributed data. Correlation analysis was performed by means of a Spearman correlation. Level of significance was established at α = 0.05. Graph pad prism 5.0 (Graph Pad Software, USA) and SPSS v. 18 (Microsoft, USA) were used for the analysis of the data.

Results

The analysis of gene expression of the type I IFN pathway has been associated with increased inflammatory responses in other autoimmune disease such as SLE. There is limited information regarding the role of the transcriptional pathway and the relationship that this might have with the inflammatory response in RA in the early stages of the disease and in the high-risk ACPA+ individuals. Therefore, we evaluated the gene expression of several genes associated with the IFN signature in the Mexican population. Given that several genes regulated by type I IFN can be grouped into several functions, such differences are described below. No differences in gender proportions were identified, and all patients belonged to a Mexican Mestizo population, which was not characterized for the presence of HLA-risk Alleles. All patients were treated (in case of RA patients) with DMARD, and methotrexate was used most frequently.

Antiviral Response Genes of the IFN Signature Are Overexpressed in RA

An increased expression of the MXA mRNA was found when comparing the established RA (cRA) group with the high-risk group (ACPA+) and also with the control groups (both ACPA− and HC) as shown in Figure Figure1A1A (P < 0.05). No differences in gene expression were found for the eRA group in any comparison for this gene. MXB, another gene, involved in the antiviral response mediated by the type I IFN response was also found to have an increased expression when compared with the control groups (HC and ACPA−) and with the ACPA+ group (Figure (Figure1B,1B, P < 0.05), and the same pattern of increase across groups is observed as in MXA.

Figure 1
Analysis of gene expression associated with antiviral response. Gene expression analysis was carried out in cDNA synthesized from blood total RNA to assess the relative gene expression profile of type I interferon-related genes: (A) MXA and (B) MXB genes ...

Transcriptional Regulators of IFN Signature Are Overexpressed in Established RA

IFIT1 gene expression was evaluated in the samples of the previously described groups. Significant differences were identified when comparing cRA with ACPA− individuals (Figure (Figure2A,2A, P < 0.05). Similar observations can be made for the IFIT2 gene that belongs to the same family of transcriptional regulators; significant differences were identified for this gene between the cRA and both the ACPA and HC groups (Figure (Figure2B,2B, P < 0.05).

Figure 2
Gene expression of the posttranscriptional regulators IFIT1 and IFIT2. Gene expression analysis was carried out in cDNA synthesized from blood total RNA to assess the relative gene expression profile of type I interferon-related genes: (A) IFIT1 and ...

Overexpression in Established RA of the Proteasomal Degradation Machinery of the IFN Signature

Regulation of protein degradation is a hallmark of the type I IFN signature, and given their role in antigen presentation by class I molecules of due to cross-priming, the expression of the “ISGlation” machinery of proteasomal degradation was also evaluated. Significant differences in gene expression were found for both the ISG15 and the HERC5 mRNAs when comparing the established disease patients with HC (Figures (Figures3A,B,3A,B, respectively). Also, a tendency toward the increase is observed in the natural history of the disease.

Figure 3
Interferon (IFN)-1 signature genes associated with induction of proteasomal degradation. Gene expression analysis was carried out in cDNA synthesized from blood total RNA to assess the relative gene expression profile of type I IFN-related genes: (A) ...

Increased Expression of Proliferation Regulators of the IFN Signature in RA Patients

Proliferation and expansion of B cells is of major importance in inflammatory autoimmune diseases due to the generation of pathogenic antibodies. Given that several genes of the IFN signature pathway are associated with the regulation of proliferation in B cells, we sought to evaluate the expression of such genes in this phenomenon. Ly6E expression showed significant differences between established RA (cRA) and the ACPA− first-degree relatives and HC as shown in Figure Figure4A4A (P < 0.05). Also, RSAD2 has been shown to have similar functions, participating in the control of expansion of several immune cells (44). Significant differences were identified when comparing not only established RA (cRA) with HC but also the ACPA+ with HC, suggesting their involvement in early preclinical features of the disease and in the established inflammatory milieu of arthritis (Figure (Figure4B,4B, P < 0.05).

Figure 4
Analysis of gene expression of the interferon (IFN)-1 signature associated with increased proliferation. Gene expression analysis was carried out in cDNA synthesized from blood total RNA to assess the relative gene expression profile of type I IFN-related ...

IFI6, IFI35, and EPSTRI1 Gene Expression Is Increased in RA

Other genes of the IFN signature such as IFI6 have been associated with apoptosis regulation (IFI6 and IFI35), epithelial to mesenchymal transition (EPSTRI1), and other functions. There is an increase in the EPSTRI1 gene expression in the cRA group compared to HC (Figure (Figure5A,5A, P < 0.05). No differences were found for IFI44L gene expression for any of the groups analyzed (Figure (Figure5B,5B, P > 0.05). A significant higher expression of IFI6 was observed in the eRA group compared to ACPA− individuals and HC (Figure (Figure5C,5C, P < 0.05). IFI35 also showed significant differences in the cRA group when compared to HC (Figure (Figure5D,5D, P < 0.05).

Figure 5
Genes associated with miscellaneous functions in the interferon (IFN)-1 signature. Gene expression analysis was carried out in cDNA synthesized from blood total RNA to assess the relative gene expression profile of type I IFN-related genes: (A) EPSTRLI1, ...

Autoantibodies against Carbamylated and Citrullinated Proteins Correlate with the Expression Levels of Several Type I IFN-Regulated Genes

Given the importance of several of the abovementioned genes in the regulation of proliferation of immune cells, as well as in the response in the antiviral response and (indirectly) in antigen presentation and consequently in the generation of antibodies by differentiation of B cells into plasmatic antibody-secreting cells, we wondered whether autoantibody levels might be associated with the gene expression of the IFN signature. After a non-parametric Spearman correlation analysis, we identified significant correlations with the levels of anti-CarP antibodies for IFI6, IFI35, ISG15, Ly6E, and MXA (Spearman r, 0.249–0.352, P < 0.05; Table Table2).2). In addition, significant correlations were identified for 8 of the 12 IFN signature genes (IFI6, IFIT2, IFI35, ISG15, MXB, Ly6E, EPSTRI1, and MXA; Spearman r, 0.227–0.476, P < 0.05), suggesting an important participation of the gene regulation mediated by the IFN signature in autoantibody generation. Also a trend for the increase of both anti-CarP and ACPA is observed when comparing for the natural history of the disease (data not shown).

Table 2
Correlation analyses of autoantibody levels [anticitrullinated protein antibodies (ACPA) and anticarbamylated protein (anti-carP) antibodies] with relative expression of interferon-1 signature genes.

Discussion

Rheumatoid arthritis is an inflammatory disease that is characterized by the generation of autoreactive clones of T and B cells and, in consequence, by the generation of autoantibodies (45). It has been proposed that autoantibodies could be involved in the generation of IFN through the activation of the pDC, and it could be implicated in the perpetuation of the inflammatory process as has been previously described for LES (46, 47). The first report that linked the IFN signature with autoimmunity in RA came from Van der Paw; he found an elevation in the expression pattern of several of the genes of the pathway in the established disease (25). However, little has been done to try to replicate such data in other populations and settings. Here, we report the analysis of several genes of the type I IFN signature and its relationship with high-risk individuals (ACPA+), eRA, and established RA and the participation of such genes in the physiopathology of the disease in different stages and their possible use as biomarkers in early stages of disease. Also, we discuss the association between the presence of anti-CarP and ACPA and the potential role of the type I IFN signature genes in the generation of such antibodies.

It has been reported that some chronic viral infections might be the trigger or at least are associated with, of autoimmunity, in particular due to cross-reactivity, as has been observed in several tropical viral infections such as Chikungunya (48), Epstein-Barr (49), and Zika (50), which have been associated with acute arthritis of unknown origin and have been poorly characterized (51, 52). In this regard, several genes of the IFN signature such as MXA and MXB have been associated with protection against viral infection (53, 54). Our data clearly show an increased expression of the MXA and MXB genes providing evidence of the role that these molecules might have in the induction of inflammation in the early phases of RA or even previous to the onset of symptoms in individuals at high risk, with the possible involvement of such molecules even in the preclinical autoimmune phase of RA, explaining just in part the lack of differences in the established phase of the disease. The risk of developing RA associated with increased expression of these genes needs to be further evaluated in the light of the induction of tolerance processes and determine whether MXA and MXB gene expression increase is due to viral infection and/or the generation of interferogenic complexes.

Recently, a strong association between RA and the unfolded protein response (UPR) was described (5557), and therefore, the regulation of the transcription/translation process has been put on the spotlight of RA pathogenesis. It has been described that several regulators of the translation of proteins particularly GADD34 are associated with the UPR in RA (55); however, little attention has been put to the transcriptional process and their regulators such as IFIT1 and IFIT2 that are known to regulate the apoptotic process (58). In this regard, we found an increased expression of these genes in the established disease phase. Suggesting that the role of the transcriptional regulation in the chronic phase of RA might be associated with the activation of the immune response by type I IFN; also, given that due to medication several viral infections become recurrent in these patients (59), upregulation of IFIT1 and IFIT2 could be associated with these infections in RA. Also the role of other regulators in the expression of these genes such as miRNA needs to be further evaluated, and also the viral subclinical infection status of such individuals (Epstein-Barr virus and cytomegalovirus infection status) needs to be determined.

The mechanisms of ubiquitination are very important for the clearance of several proteins within the cell and therefore are related to the UPR (60). ISG15 is a small ubiquitin molecule associated with antiviral response in a process called “ISGlation” (61). It has been described that this molecule can regulate the activity of negative regulator IRF3 and in this way promotes the expression of genes of the IFN signature (62). Further research on the role of HERC5 and ISG15 in RA pathogenesis is needed to establish their participation in experimental models of RA and to evaluate how is regulated in the early phases of disease or if the phenomenon is exclusively associated with chronic inflammatory processes as observed in the established disease patients. Also, the potential use of these molecules as markers of treatment success has been described previously by Raterman and colleagues (63).

The regulation of apoptosis may also play an important role in the pathogenesis of RA (13). Little is known about the function of IFI6, and it has been described that IFI6 inhibits apoptosis trough the downregulation of caspase 3 and casase 9 (64). This effect might be associated with increased survival of inflammatory cells that perpetuate the activation of antibody-producing B cells, and this needs to be further evaluated. Also, Ly6E has been associated with an increased proliferation in several cell lineages (65) and could mediate the process of B cell expansion in inflammatory disorders through a TGF-beta-mediated mechanism, but this needs to be further explored. RSAD2 (also known as Viperin) is an antiviral protein associated with regulation of proliferation of immune cells, and it has been associated with Th2 polarization of immune cells through a mechanism mediated by GATA3, NF-κB, and IL-4 production, therefore inducing and modulating the production of autoantibodies (44). The increased expression of RSAD2 in ACPA+ individuals and cRA patients might contribute to autoantibody generation. The increased expression of this pathway needs to be further elucidated given that expression of these molecules is mainly regulated by viral infection (6668).

There is no clear evidence if the perpetuation of the inflammatory process through the activation of inflammatory cells might be associated with increased levels of antibodies in several stages of the disease (69, 70). For this purpose, we analyzed the expression of several genes of the type IFN gene signature in groups of individuals who had no previous family history of the disease, HC, and also in individuals with ACPA−, ACPA+, eRA, and cRA, which accounts for the natural history of the disease. We found a significant correlation between the expression of these genes associated with proliferation control of B cell maturation and antibody production such as IFI6, IFI35, ISG15, EPSTRI1, MXA, and Ly6E, several of which are associated with promotion of B cell differentiation and antibody production (71). Our results differ from those of other groups in which no association has been found for autoantibody production of ACPA and other autoantibodies (RF, antinucleosome, etc.) in adalimumab-treated patients (72), which has been recently confirmed to modify the gene expression pattern of the type I IFN signature in neutrophils of patients with RA (73). Also the authors did not analyze the correlation effect of the IFN signature gene expression on the antibodies that were analyzed, neither did they analyze the anti-CarP antibodies. Another substantial difference that may account for the differences in our findings and that of Cantaert et al is that we included individuals (eRA) who were virgin to treatment (72). Our groups of individuals were recruited in an attempt to emulate the natural history of disease in a patient with RA, and therefore, the tendency is clear to increase the levels of autoantibodies in the late phases of disease. Ethnic and population differences may also account for such differences (74, 75).

Although our correlation analysis cannot be confirmed as causality, it clearly highlights the association of the increased expression of Type I IFN response genes with the master regulators of B cell development, and differentiation into plasma cells might be of pivotal importance in the generation of autoantibodies in RA, which has been already described in SLE (76) and some myopathies (77). Further mechanistic studies are needed to confirm such association and describe the detailed mechanism.

This article provides evidence of the limited use of the gene expression of these markers to differentiate the early stages of RA, although MXA, MXB, and IFI6 showed an increased expression when compared to HC. The participation of several genes of the IFN signature is also described in the context of the available data on the pathogenesis of the disease. We describe a plausible link between type I IFN-induced gene expression and the generation of anti-CarP antibodies and ACPA. Limitations of the study include sample size and previous DMARD use in the cRA group.

Author Contributions

JC-D, YB-H, LE-M, DO-C, DS-A, and AA-N: manuscript, experiment, analysis, and idea conception; CR-R, JC, and PM-T: supervision and sample collection; JE-M: overall supervision, analysis, manuscript approval, and conception of idea.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to thank to physicians, clinical and laboratory staff, and the study subjects (patients and their families for the time and committed participation). Funding was received from IMSS projects # PROT FIS IMSS PROT G16 1578 and #FIS/IMSS/PROT/PRIO/13/028.

Supplmentary Material

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00285/full#supplementary-material.

References

1. Kaarela K, Kauppi MJ, Lehtinen KE.. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol (1995) 24(5):279–81.10.3109/03009749509095163 [PubMed] [Cross Ref]
2. Tobon GJ, Youinou P, Saraux A.. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun (2010) 35(1):10–4.10.1016/j.jaut.2009.12.009 [PubMed] [Cross Ref]
3. Escalante A, del Rincon I.. How much disability in rheumatoid arthritis is explained by rheumatoid arthritis? Arthritis Rheum (1999) 42(8):1712–21.10.1002/1529-0131(199908)42:8<1712::AID-ANR21>3.0.CO;2-X [PubMed] [Cross Ref]
4. Mould-Quevedo J, Pelaez-Ballestas I, Vazquez-Mellado J, Teran-Estrada L, Esquivel-Valerio J, Ventura-Rios L, et al. [Social costs of the most common inflammatory rheumatic diseases in Mexico from the patient’s perspective]. Gac Med Mex (2008) 144(3):225–31. [PubMed]
5. Pratesi F, Petit Teixeira E, Sidney J, Michou L, Puxeddu I, Sette A, et al. HLA shared epitope and ACPA: just a marker or an active player? Autoimmun Rev (2013) 12(12):1182–7.10.1016/j.autrev.2013.08.002 [PubMed] [Cross Ref]
6. Korczowska I.. Rheumatoid arthritis susceptibility genes: an overview. World J Orthop (2014) 5(4):544–9.10.5312/wjo.v5.i4.544 [PMC free article] [PubMed] [Cross Ref]
7. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis (2010) 69(1):70–81.10.1136/ard.2008.096487 [PubMed] [Cross Ref]
8. Kaur S, Bright R, Proudman SM, Bartold PM.. Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. Semin Arthritis Rheum (2014) 44(2):113–22.10.1016/j.semarthrit.2014.04.009 [PubMed] [Cross Ref]
9. Ramos-Remus C, Sierra-Jimenez G, Skeith K, Aceves-Avila FJ, Russell AS, Offer R, et al. Latitude gradient influences the age of onset in rheumatoid arthritis patients. Clin Rheumatol (2007) 26(10):1725–8.10.1007/s10067-007-0666-2 [PubMed] [Cross Ref]
10. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. Pesticides and oxidative stress: a review. Med Sci Monit (2004) 10(6):RA141–7. [PubMed]
11. Scott DL, Wolfe F, Huizinga TW.. Rheumatoid arthritis. Lancet (2010) 376(9746):1094–108.10.1016/S0140-6736(10)60826-4 [PubMed] [Cross Ref]
12. Christmann RB, Sampaio-Barros P, Stifano G, Borges CL, de Carvalho CR, Kairalla R, et al. Association of interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol (2014) 66(3):714–25.10.1002/art.38288 [PMC free article] [PubMed] [Cross Ref]
13. Meinecke I, Cinski A, Baier A, Peters MA, Dankbar B, Wille A, et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci U S A (2007) 104(12):5073–8.10.1073/pnas.0608773104 [PubMed] [Cross Ref]
14. Leech MT, Morand EF.. Fibroblasts and synovial immunity. Curr Opin Pharmacol (2013) 13(4):565–9.10.1016/j.coph.2013.04.001 [PubMed] [Cross Ref]
15. Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA.. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther (2007) 9(2):R25.10.1186/ar2137 [PMC free article] [PubMed] [Cross Ref]
16. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med (2013) 5(178):178ra40.10.1126/scitranslmed.3005580 [PMC free article] [PubMed] [Cross Ref]
17. Romero V, Fert-Bober J, Nigrovic PA, Darrah E, Haque UJ, Lee DM, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med (2013) 5(209):209ra150.10.1126/scitranslmed.3006869 [PMC free article] [PubMed] [Cross Ref]
18. Toubi E, Shoenfeld Y.. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 37(6–7):457–64.10.1080/08916930400002386 [PubMed] [Cross Ref]
19. Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol (2000) 30(10):2815–23.10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-# [PubMed] [Cross Ref]
20. Gupta A, Kaushik R, Kaushik RM, Saini M, Kakkar R. Association of anti-cyclic citrullinated peptide antibodies with clinical and radiological disease severity in rheumatoid arthritis. Curr Rheumatol Rev (2015) 10(2):136–43.10.2174/1573397110666150120102928 [PubMed] [Cross Ref]
21. van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH.. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum (2011) 63(1):37–42.10.1002/art.30100 [PubMed] [Cross Ref]
22. Ramos-Remus C, Castillo-Ortiz JD, Aguilar-Lozano L, Padilla-Ibarra J, Sandoval-Castro C, Vargas-Serafin CO, et al. Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. Arthritis Rheumatol (2015) 67(11):2837–44.10.1002/art.39297 [PubMed] [Cross Ref]
23. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum (2013) 65(4):911–5.10.1002/art.37830 [PubMed] [Cross Ref]
24. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis (2014) 73(4):780–3.10.1136/annrheumdis-2013-204154 [PubMed] [Cross Ref]
25. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 66(8):1008–14.10.1136/ard.2006.063412 [PMC free article] [PubMed] [Cross Ref]
26. Theofilopoulos AN, Baccala R, Beutler B, Kono DH.. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol (2005) 23:307–36.10.1146/annurev.immunol.23.021704.115843 [PubMed] [Cross Ref]
27. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN.. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med (2007) 13(5):543–51.10.1038/nm1590 [PubMed] [Cross Ref]
28. Cao W, Liu YJ.. Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol (2007) 19(1):24–30.10.1016/j.coi.2006.11.004 [PubMed] [Cross Ref]
29. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L.. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum (2004) 50(6):1861–72.10.1002/art.20254 [PubMed] [Cross Ref]
30. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum (2006) 54(2):408–20.10.1002/art.21571 [PubMed] [Cross Ref]
31. Obermoser G, Pascual V.. The interferon-alpha signature of systemic lupus erythematosus. Lupus (2010) 19(9):1012–9.10.1177/0961203310371161 [PMC free article] [PubMed] [Cross Ref]
32. Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis (2013) 72(5):776–80.10.1136/annrheumdis-2012-202753 [PubMed] [Cross Ref]
33. Haller O, Staeheli P, Schwemmle M, Kochs G.. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol (2015) 23(3):154–63.10.1016/j.tim.2014.12.003 [PubMed] [Cross Ref]
34. Samuel CE.. Antiviral actions of interferons. Clin Microbiol Rev (2001) 14(4):778–809.10.1128/CMR.14.4.778-809.2001 [PMC free article] [PubMed] [Cross Ref]
35. Zhou X, Michal JJ, Zhang L, Ding B, Lunney JK, Liu B, et al. Interferon induced IFIT family genes in host antiviral defense. Int J Biol Sci (2013) 9(2):200–8.10.7150/ijbs.5613 [PMC free article] [PubMed] [Cross Ref]
36. Fensterl V, Sen GC.. The ISG56/IFIT1 gene family. J Interferon Cytokine Res (2011) 31(1):71–8.10.1089/jir.2010.0101 [PMC free article] [PubMed] [Cross Ref]
37. Tang JP, Gu YY, Shen N, Ye S, Qian J, Hua J, et al. [Interferon-inducible genes lymphocyte antigen 6 complex E and tetratricopeptide repeats 1 are correlated with clinical features of patients with systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi (2004) 84(14):1157–60. [PubMed]
38. Yang W, Tan J, Liu R, Cui X, Ma Q, Geng Y, et al. Interferon-gamma upregulates expression of IFP35 gene in HeLa cells via interferon regulatory factor-1. PLoS One (2012) 7(12):e50932.10.1371/journal.pone.0050932 [PMC free article] [PubMed] [Cross Ref]
39. Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC.. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest (2007) 117(10):3107–17.10.1172/JCI31122 [PubMed] [Cross Ref]
40. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med (2008) 205(2):315–22.10.1084/jem.20070763 [PMC free article] [PubMed] [Cross Ref]
41. Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 64(9):2824–35.10.1002/art.34498 [PMC free article] [PubMed] [Cross Ref]
42. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 62(9):2569–81.10.1002/art.27584 [PubMed] [Cross Ref]
43. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A (2011) 108(42):17372–7.10.1073/pnas.1114465108 [PubMed] [Cross Ref]
44. Qiu LQ, Cresswell P, Chin KC.. Viperin is required for optimal Th2 responses and T-cell receptor-mediated activation of NF-kappaB and AP-1. Blood (2009) 113(15):3520–9.10.1182/blood-2008-07-171942 [PubMed] [Cross Ref]
45. Singh RR, Ebling FM, Albuquerque DA, Saxena V, Kumar V, Giannini EH, et al. Induction of autoantibody production is limited in nonautoimmune mice. J Immunol (2002) 169(1):587–94.10.4049/jimmunol.169.1.587 [PubMed] [Cross Ref]
46. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Ronnblom L.. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus (2001) 10(7):484–90.10.1191/096120301678416042 [PubMed] [Cross Ref]
47. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL.. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol (2001) 159(1):237–43.10.1016/S0002-9440(10)61689-6 [PubMed] [Cross Ref]
48. Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A.. Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum (2012) 64(11):3553–63.10.1002/art.34631 [PMC free article] [PubMed] [Cross Ref]
49. Westergaard MW, Draborg AH, Troelsen L, Jacobsen S, Houen G.. Isotypes of Epstein-Barr virus antibodies in rheumatoid arthritis: association with rheumatoid factors and citrulline-dependent antibodies. Biomed Res Int (2015) 2015:472174.10.1155/2015/472174 [PMC free article] [PubMed] [Cross Ref]
50. Plourde AR, Bloch EM.. A literature review of Zika virus. Emerg Infect Dis (2016) 22(7):1185–92.10.3201/eid2207.151990 [PMC free article] [PubMed] [Cross Ref]
51. Vijayan V, Sukumaran S.. Chikungunya virus disease: an emerging challenge for the rheumatologist. J Clin Rheumatol (2016) 22(4):203–11.10.1097/RHU.0000000000000396 [PubMed] [Cross Ref]
52. Draborg A, Izarzugaza JM, Houen G.. How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases? Curr Opin Rheumatol (2016) 28(4):398–404.10.1097/BOR.0000000000000289 [PubMed] [Cross Ref]
53. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, et al. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology (2014) 11:68.10.1186/PREACCEPT-6453674081373986 [PMC free article] [PubMed] [Cross Ref]
54. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, et al. Host and viral determinants of Mx2 antiretroviral activity. J Virol (2014) 88(14):7738–52.10.1128/JVI.00214-14 [PMC free article] [PubMed] [Cross Ref]
55. Clavarino G, Adriouach S, Quesada JL, Clay M, Chevreau M, Trocme C, et al. Unfolded protein response gene GADD34 is overexpressed in rheumatoid arthritis and related to the presence of circulating anti-citrullinated protein antibodies. Autoimmunity (2016) 49(3):172–8.10.3109/08916934.2016.1138220 [PubMed] [Cross Ref]
56. Park YJ, Yoo SA, Kim WU.. Role of endoplasmic reticulum stress in rheumatoid arthritis pathogenesis. J Korean Med Sci (2014) 29(1):2–11.10.3346/jkms.2014.29.1.2 [PMC free article] [PubMed] [Cross Ref]
57. Li L, Zhu J, Huang F.. [The expression and significance of unfolded protein response-related gene in synovial fluid macrophages in patients with spondyloarthritis and other arthritis]. Zhonghua Nei Ke Za Zhi (2013) 52(7):574–7. [PubMed]
58. Lai KC, Chang KW, Liu CJ, Kao SY, Lee TC.. IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma. Mol Cancer Res (2008) 6(9):1431–9.10.1158/1541-7786.MCR-08-0141 [PubMed] [Cross Ref]
59. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL.. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis (2016) 75(10):1843–7.10.1136/annrheumdis-2016-209131 [PubMed] [Cross Ref]
60. Zhang L, Hapon MB, Goyeneche AA, Srinivasan R, Gamarra-Luques CD, Callegari EA, et al. Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Mol Oncol (2016) 10(7):1099–117.10.1016/j.molonc.2016.05.001 [PMC free article] [PubMed] [Cross Ref]
61. Durfee LA, Lyon N, Seo K, Huibregtse JM.. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol Cell (2010) 38(5):722–32.10.1016/j.molcel.2010.05.002 [PMC free article] [PubMed] [Cross Ref]
62. Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol (2010) 30(10):2424–36.10.1128/MCB.01466-09 [PMC free article] [PubMed] [Cross Ref]
63. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 14(2):R95.10.1186/ar3819 [PMC free article] [PubMed] [Cross Ref]
64. Qi Y, Li Y, Zhang Y, Zhang L, Wang Z, Zhang X, et al. IFI6 inhibits apoptosis via mitochondrial-dependent pathway in dengue virus 2 infected vascular endothelial cells. PLoS One (2015) 10(8):e0132743.10.1371/journal.pone.0132743 [PMC free article] [PubMed] [Cross Ref]
65. AlHossiny M, Luo L, Frazier WR, Steiner N, Gusev Y, Kallakury B, et al. Ly6E/K signaling to TGFbeta promotes breast cancer progression, immune escape, and drug resistance. Cancer Res (2016) 76(11):3376–86.10.1158/0008-5472.CAN-15-2654 [PMC free article] [PubMed] [Cross Ref]
66. Helbig KJ, Beard MR.. The role of viperin in the innate antiviral response. J Mol Biol (2014) 426(6):1210–9.10.1016/j.jmb.2013.10.019 [PubMed] [Cross Ref]
67. Mattijssen S, Pruijn GJ.. Viperin, a key player in the antiviral response. Microbes Infect (2012) 14(5):419–26.10.1016/j.micinf.2011.11.015 [PubMed] [Cross Ref]
68. Seo JY, Yaneva R, Cresswell P.. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe (2011) 10(6):534–9.10.1016/j.chom.2011.11.004 [PMC free article] [PubMed] [Cross Ref]
69. Dekkers J, Toes RE, Huizinga TW, van der Woude D.. The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. Curr Opin Rheumatol (2016) 28(3):275–81.10.1097/BOR.0000000000000277 [PubMed] [Cross Ref]
70. Kerkman PF, Rombouts Y, van der Voort EI, Trouw LA, Huizinga TW, Toes RE, et al. Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis (2013) 72(7):1259–63.10.1136/annrheumdis-2012-202893 [PubMed] [Cross Ref]
71. Palanichamy A, Bauer JW, Yalavarthi S, Meednu N, Barnard J, Owen T, et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol (2014) 192(3):906–18.10.4049/jimmunol.1302112 [PMC free article] [PubMed] [Cross Ref]
72. Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (2010) 49(1):156–66.10.1093/rheumatology/kep345 [PubMed] [Cross Ref]
73. Wright HL, Thomas HB, Moots RJ, Edwards SW.. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (2015) 54(1):188–93.10.1093/rheumatology/keu299 [PubMed] [Cross Ref]
74. Mendoza Rincon JF, Rodriguez Elias AK, Fragoso JM, Vargas Alarcon G, Maldonado Murillo K, Rivas Jimenez ML, et al. MHC2TA and FCRL3 genes are not associated with rheumatoid arthritis in Mexican patients. Rheumatol Int (2016) 36(2):249–54.10.1007/s00296-015-3358-2 [PubMed] [Cross Ref]
75. Guzman-Guzman IP, Reyes-Castillo Z, Munoz-Barrios S, Ruiz-Noa Y, Martinez-Bonilla GE, Parra-Rojas I, et al. Polymorphisms and functional haplotype in PADI4: further evidence for contribution on rheumatoid arthritis susceptibility and anti-cyclic citrullinated peptide antibodies in a western Mexican population. Immunol Lett (2015) 163(2):214–20.10.1016/j.imlet.2014.10.029 [PubMed] [Cross Ref]
76. Biesen R, Rose T, Hoyer BF, Alexander T, Hiepe F.. Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. Lupus (2016) 25(8):823–9.10.1177/0961203316640922 [PubMed] [Cross Ref]
77. Ekholm L, Vosslamber S, Tjarnlund A, de Jong T, Betteridge Z, McHugh N, et al. Autoantibody specificities and type I interferon pathway activation in idiopathic inflammatory myopathies. Scand J Immunol (2016) 84(2):100–9.10.1111/sji.12449 [PubMed] [Cross Ref]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA